UBS Group
RCEL icon

UBS Group’s Avita Medical RCEL Stock Holding History

UBS Group’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Buy
84,033
+21,579
+35% +$93.1K ﹤0.01% 6456
2026
Q1 		$231K Sell
62,454
-27,855
-31% -$117K ﹤0.01% 6553
2025
Q4 		$312K Buy
90,309
+14,909
+20% +$59.5K ﹤0.01% 6341
2025
Q3 		$385K Sell
75,400
-334,399
-82% -$1.74M ﹤0.01% 6270
2025
Q2 		$2.17M Buy
409,799
+65,071
+19% +$473K ﹤0.01% 4735
2025
Q1 		$2.81M Buy
344,728
+216,098
+168% +$2.02M ﹤0.01% 4390
2024
Q4 		$1.65M Buy
128,630
+110,824
+622% +$1.31M ﹤0.01% 4915
2024
Q3 		$191K Buy
17,806
+686
+4% +$6.44K ﹤0.01% 5909
2024
Q2 		$136K Sell
17,120
-34,396
-67% -$327K ﹤0.01% 5948
2024
Q1 		$826K Buy
51,516
+31,509
+157% +$510K ﹤0.01% 4753
2023
Q4 		$274K Buy
20,007
+7,258
+57% +$83.2K ﹤0.01% 5568
2023
Q3 		$186K Sell
12,749
-4,729
-27% -$80K ﹤0.01% 5410
2023
Q2 		$297K Buy
17,478
+11,470
+191% +$168K ﹤0.01% 5210
2023
Q1 		$83.9K Buy
6,008
+5,282
+728% +$56.2K ﹤0.01% 6055
2022
Q4 		$4.79K Buy
726
+476
+190% +$2.85K ﹤0.01% 9278
2022
Q3 		$1K Sell
250
-1,023
-80% -$6.32K ﹤0.01% 10017
2022
Q2 		$6K Sell
1,273
-136
-10% -$840 ﹤0.01% 8711
2022
Q1 		$13K Sell
1,409
-35,820
-96% -$330K ﹤0.01% 8071
2021
Q4 		$445K Buy
37,229
+21,042
+130% +$321K ﹤0.01% 5072
2021
Q3 		$287K Buy
16,187
+14,987
+1,249% +$283K ﹤0.01% 5071
2021
Q2 		$25K Sell
1,200
-12,922
-92% -$255K ﹤0.01% 7112
2021
Q1 		$280K Buy
14,122
+12,271
+663% +$285K ﹤0.01% 5255
2020
Q4 		$35K Buy
1,851
+1,651
+826% +$36.2K ﹤0.01% 6508
2020
Q3 		$5K Sell
200
-959
-83% -$23.9K ﹤0.01% 7328
2020
Q2 		$35K Buy
1,159
+959
+480% +$29.3K ﹤0.01% 6172
2020
Q1 		$6K Sell
200
-871
-81% -$36.1K ﹤0.01% 7229
2019
Q4 		$49K Buy
+1,071
New +$44.5K ﹤0.01% 6359

Other funds holding RCEL

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group's RCEL Position: Q2 2026 in Review

UBS Group increased its Avita Medical (RCEL) stake by 35% in Q2 2026, buying an estimated $93.1K and bringing the position to 84,033 shares worth $347K. The position accounts for ﹤0.01% of the portfolio, ranked #6456.

UBS Group first reported a position in RCEL in Q4 2019 and has held it in 27 quarters since. The position peaked at $2.81M in Q1 2025. 74 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

  • UBS Group held 84,033 shares of Avita Medical worth $347K as of Q2 2026.
  • UBS Group bought 21,579 Avita Medical shares in Q2 2026, an estimated $93.1K.
  • Avita Medical made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6456 holding.
  • UBS Group first reported a position in Avita Medical in Q4 2019 and has held it in 27 quarters since.
  • UBS Group's Avita Medical position peaked at $2.81M in Q1 2025.
  • 74 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.